DOI: https://doi.org/10.36347/sjmcr.2025.v13i01.021

Pages: 100-101

Introduction: Quetiapine is an atypical antipsychotic that acts as an antagonist on serotonin, dopamine, histamine, and adrenergic receptors. It is approved for the treatment of schizophrenia and mood disorders and is commonly used off-label for depression, anxiety, and insomnia. Common side effects include drowsiness, dizziness, and headaches. Although hair loss is a rare side effect of psychotropic medications, it has been reported with certain drugs but remains poorly documented. Case: We report the case of a 37-year-old man treated for major depressive disorder who experienced hair loss after two months of quetiapine treatment. Following the discontinuation of quetiapine, hair loss stopped, and hair regrowth was observed. Discussion: This is the first documented case in Morocco associating quetiapine with hair loss. Telogen effluvium, a condition of hair loss often triggered by stress or medications, can occur with psychotropic drugs like certain mood stabilizers and antipsychotics. Similar cases have been reported in New Zealand, Turkey, and Germany. Conclusion: Quetiapine is widely prescribed in Morocco, but this case highlights the need for awareness regarding rare side effects like hair loss. This study suggests a reevaluation of quetiapine’s tolerability and encourages further research to better understand these potential side effects and improve prescribing practices.